1. Apoptosis
  2. TNF-alpha

Lenalidomide (Synonyms: CC-5013)

Cat. No.: HY-A0003 Purity: 99.98%
Data Sheet SDS Handling Instructions

Lenalidomide is a potent inhibitor of TNF-α and has antiangiogenic effect.

For research use only. We do not sell to patients.
Lenalidomide Chemical Structure

Lenalidomide Chemical Structure

CAS No. : 191732-72-6

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
100 mg $50 In-stock
500 mg $90 In-stock
1 g $150 In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

Other Forms of Lenalidomide:

    Lenalidomide purchased from MCE. Usage Cited in: Nat Commun. 2017 May 22;8:15398.

    HEK293T cells are treated with 50 μg/mL Cycloheximide and increasing concentrations of Lenalidomide, Thalidomide or with DMSO, and cells are incubated for 6 h. ZFP91 and GAPDH levels are detected using anti-ZFP91 or anti-GAPDH immunoblotting.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    Lenalidomide is a potent inhibitor of TNF-α and has antiangiogenic effect.

    IC50 & Target

    TNF-α[1]

    In Vitro

    Lenalidomide is potent in stimulating T cell proliferation and IFN-γ and IL-2 production. Lenalidomide has been shown to inhibit production of pro inflammatory cytokines TNF-α, IL-1, IL-6, IL-12 and elevate the production of anti-inflammatory cytokine IL-10 from human PBMCs. Lenalidomide downregulates the production of IL-6 directly and also by inhibiting multiple myeloma (MM) cells and bone marrow stromal cells (BMSC) interaction, which augments the apoptosis of myeloma cells[2]. Dose-dependent interaction with the CRBN-DDB1 complex is observed with Thalidomide, Lenalidomide and Pomalidomide, with IC50 values of ~30 μM, ~3 μM and ~3 μM, respectively, These reduced CRBN expression cells (U266-CRBN60 and U266-CRBN75) are less responsive than the parental cells to antiproliferative effects Lenalidomide across a dose-response range of 0.01 to 10 μM[3].

    In Vivo

    The toxicity of Lenalidomide doses up to 15, 22.5, and 45 mg/kg via IV, IP, and PO routes of administration. Limited by solubility in our PBS dosing vehicle, these maximum achievable Lenalidomide doses are well tolerated with the exception of one mouse death (of four total dosed) at the 15 mg/kg IV dose. Notably, no other toxicities are observed in the study at IV doses of 15 mg/kg (n=3) or 10 mg/kg (n=45) or at any other dose level through IV, IP, and PO routes[4].

    Clinical Trial
    NCT Number Sponsor Condition Start Date Phase
    NCT00055562 Celgene Corporation|Celgene Melanoma|Neoplasm Metastasis January 2003 Phase 2|Phase 3
    NCT00064974 Celgene Corporation|Celgene Myelodysplastic Syndromes June 2003 Phase 2
    NCT00153933 Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|H. Lee Moffitt Cancer Center and Research Institute Refractory Multiple Myeloma|Relapsed Multiple Myeloma|Multiple Myeloma August 2004 Phase 1
    NCT00087672 M.D. Anderson Cancer Center|Celgene Corporation Myelofibrosis July 2004 Phase 2
    NCT00056160 Celgene Multiple Myeloma January 2003 Phase 3
    NCT00166413 Mayo Clinic Amyloidosis April 2005 Phase 2
    NCT00065351 Celgene Corporation Multiple Myeloma July 2003 Phase 2
    NCT01155505 Southern Europe New Drug Organization|Celgene Corporation Advanced Solid Tumors November 2009 Phase 1
    NCT00044382 Celgene Corporation|Celgene Myelodysplastic Syndrome February 2002 Phase 2
    NCT00051116 Celgene Corporation|Celgene Multiple Myeloma May 2002 Phase 2
    NCT00091624 Celgene Corporation Multiple Myeloma March 2003 Phase 1
    NCT00179699 Celgene Corporation|Prologue Research International|Celgene Non-Small Cell Lung Cancer September 2005 Phase 1
    NCT00446433 Celgene Corporation Crohn's Disease March 2002 Phase 2
    NCT00179725 Celgene Corporation|Prologue Research International|Celgene Ovarian Cancer November 2005 Phase 1|Phase 2
    NCT00179686 Celgene Corporation|Prologue Research International|Celgene Non-Small Cell Lung Cancer March 2005 Phase 2
    NCT00057616 Celgene|ICON Clinical Research Melanoma|Neoplasm Metastasis October 2002 Phase 3
    NCT00120120 Celgene Corporation|Celgene Radiculopathy January 2005 Phase 2|Phase 3
    NCT00179751 Celgene Corporation|Prologue Research International|Celgene Pancreatic Cancer April 2005 Phase 1|Phase 2
    NCT00179712 Celgene Corporation|Prologue Research International Ovarian Cancer April 2005 Phase 1|Phase 2
    NCT00179608 Celgene Corporation|Prologue Research International Malignant Melanoma September 2005 Phase 1
    NCT00396045 University of Turin, Italy Multiple Myeloma January 2005 Phase 1|Phase 2
    NCT00474188 Celgene Corporation|Celgene Diffuse Large B-cell Lymphoma May 2007 Phase 2
    NCT00093028 University of Arkansas Multiple Myeloma January 2004 Phase 3
    NCT00179738 Celgene Corporation|Prologue Research International|Celgene Prostate Cancer April 2005 Phase 2
    NCT00055562 Celgene Corporation|Celgene Melanoma|Neoplasm Metastasis January 2003 Phase 2|Phase 3
    NCT00064974 Celgene Corporation|Celgene Myelodysplastic Syndromes June 2003 Phase 2
    NCT00153933 Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|H. Lee Moffitt Cancer Center and Research Institute Refractory Multiple Myeloma|Relapsed Multiple Myeloma|Multiple Myeloma August 2004 Phase 1
    NCT00087672 M.D. Anderson Cancer Center|Celgene Corporation Myelofibrosis July 2004 Phase 2
    NCT00056160 Celgene Multiple Myeloma January 2003 Phase 3
    NCT00166413 Mayo Clinic Amyloidosis April 2005 Phase 2
    NCT00065351 Celgene Corporation Multiple Myeloma July 2003 Phase 2
    NCT01155505 Southern Europe New Drug Organization|Celgene Corporation Advanced Solid Tumors November 2009 Phase 1
    NCT00044382 Celgene Corporation|Celgene Myelodysplastic Syndrome February 2002 Phase 2
    NCT00051116 Celgene Corporation|Celgene Multiple Myeloma May 2002 Phase 2
    NCT00091624 Celgene Corporation Multiple Myeloma March 2003 Phase 1
    NCT00179699 Celgene Corporation|Prologue Research International|Celgene Non-Small Cell Lung Cancer September 2005 Phase 1
    NCT00446433 Celgene Corporation Crohn's Disease March 2002 Phase 2
    NCT00179725 Celgene Corporation|Prologue Research International|Celgene Ovarian Cancer November 2005 Phase 1|Phase 2
    NCT00179686 Celgene Corporation|Prologue Research International|Celgene Non-Small Cell Lung Cancer March 2005 Phase 2
    NCT00057616 Celgene|ICON Clinical Research Melanoma|Neoplasm Metastasis October 2002 Phase 3
    NCT00120120 Celgene Corporation|Celgene Radiculopathy January 2005 Phase 2|Phase 3
    NCT00179751 Celgene Corporation|Prologue Research International|Celgene Pancreatic Cancer April 2005 Phase 1|Phase 2
    NCT00179712 Celgene Corporation|Prologue Research International Ovarian Cancer April 2005 Phase 1|Phase 2
    NCT00179608 Celgene Corporation|Prologue Research International Malignant Melanoma September 2005 Phase 1
    NCT00396045 University of Turin, Italy Multiple Myeloma January 2005 Phase 1|Phase 2
    NCT00474188 Celgene Corporation|Celgene Diffuse Large B-cell Lymphoma May 2007 Phase 2
    NCT00093028 University of Arkansas Multiple Myeloma January 2004 Phase 3
    NCT00179738 Celgene Corporation|Prologue Research International|Celgene Prostate Cancer April 2005 Phase 2
    NCT02371577 University of California, San Diego|Celgene Corporation Chronic Lymphocytic Leukemia (CLL) February 1, 2017 Phase 2
    NCT00847639 Center for International Blood and Marrow Transplant Research|National Marrow Donor Program|Celgene Corporation Multiple Myeloma February 2009 Phase 2
    NCT02279654 Celgene Myelodysplastic Syndrome December 17, 2014
    NCT02370888 University of Florida|Celgene Corporation Leukemia, Myeloid|Myelodysplastic Syndromes November 2015 Phase 1
    NCT01380106 Boston VA Research Institute, Inc.|Celgene Corporation|Kansas City Veteran Affairs Medical Center|VA Pittsburgh Healthcare System|VA Greater Los Angeles Healthcare System|Michael Debakey Veterans Affairs Medical Center|Edward Hines Jr. VA Hospital Multiple Myeloma August 2010 Phase 2
    NCT00439231 Georg Aue, M.D.|National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma February 2007 Phase 2
    NCT01724177 Celgene Adult T-Cell Leukemia-Lymphoma November 2012 Phase 2
    NCT00910858 Celgene Corporation|Celgene Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS) January 2005 Phase 1|Phase 2
    NCT00478959 University Health Network, Toronto|Celgene Corporation Hodgkin Disease December 2006 Phase 2
    NCT01057121 National Cancer Institute (NCI) AIDS-Related Kaposi Sarcoma|Recurrent Kaposi Sarcoma August 2010 Phase 1|Phase 2
    NCT00751296 University Health Network, Toronto|Celgene Chronic Lymphocytic Leukaemia August 2006 Phase 2
    NCT01198054 PETHEMA Foundation AML January 2011 Phase 4
    NCT01750762 Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute Multiple Myeloma|Lymphoma December 2012 Phase 1
    NCT00783367 Abramson Cancer Center of the University of Pennsylvania Follicular Lymphoma|Marginal Zone B-Cell Lymphoma|MALT Lymphoma|Lymphoma of Mucosa-Associated Lymphoid Tissue|Lymphoma, Small Lymphocytic|Waldenstrom Macroglobulinemia|Mantle-Cell Lymphoma July 2008 Phase 2
    NCT02126553 M.D. Anderson Cancer Center|Celgene Leukemia November 2014 Phase 2
    NCT02018523 Jun Zhang|Celgene Corporation|Baylor College of Medicine Carcinoma, Non-Small-Cell Lung June 2014 Phase 1
    NCT00179673 Celgene Corporation|Prologue Research International|Celgene Non-Hodgkins Lymphoma August 2005 Phase 2
    NCT00655668 Celgene T-cell Non-Hodgkin's Lymphoma March 2008 Phase 2
    NCT00867308 Sidney Kimmel Comprehensive Cancer Center Myelodysplastic Syndrome March 2009 Phase 2
    NCT01270932 University Health Network, Toronto Renal Failure|Multiple Myeloma November 2010 Phase 2
    NCT00812968 Celgene Corporation Myelodysplastic Syndromes September 2007 Phase 2
    NCT00799513 IRCCS San Raffaele|Celgene Corporation Diffuse Large B-cell Lymphoma October 2009 Phase 2
    NCT01379274 Rush University Medical Center|Celgene Corporation MDS January 2011 Phase 2
    NCT00761449 Nordic MDS Group MDS|AML October 2007 Phase 2
    NCT01274533 Columbia University|Celgene Corporation Adult T Cell Leukemia/Lymphoma December 2010 Phase 2
    NCT02155634 Celgene Corporation|Celgene Multiple Myeloma|Neoplasms|Plasma Cells|Paraproteinemias|Blood Protein Disorders|Hematologic Diseases|Therapeutic Uses July 2014 Phase 3
    NCT01169298 Celgene Corporation Adult T-cell Leukemia-Lymphoma|Peripheral T-cell Lymphoma July 2010 Phase 1
    NCT00704691 University of Alabama at Birmingham Peripheral T-cell Lymphomas|Adult T-cell Leukemia|Adult T-cell Lymphoma|Peripheral T-cell Lymphoma Unspecified|Angioimmunoblastic T-cell Lymphoma|Anaplastic Large Cell Lymphoma|T/Null Cell Systemic Type|Cutaneous t-Cell Lymphoma With Nodal/Visceral Disease June 2008 Early Phase 1
    NCT00874978 King's College Hospital NHS Trust Myelodysplastic Syndromes January 2005 Phase 2
    NCT01342172 Icahn School of Medicine at Mount Sinai|Celgene Corporation Urinary Bladder Neoplasms March 2011 Phase 1|Phase 2
    NCT01038635 M.D. Anderson Cancer Center|Celgene Leukemia December 2009 Phase 1|Phase 2
    NCT01750983 M.D. Anderson Cancer Center Advanced Cancers March 2013 Phase 1
    NCT00699842 Sidney Kimmel Cancer Center at Thomas Jefferson University|Celgene Corporation|Thomas Jefferson University Myelodysplastic Syndrome|MDS|Low to Intermediate-1 MDS|Non-deletion 5q July 2008 Phase 1|Phase 2
    NCT01861340 Sidney Kimmel Comprehensive Cancer Center|MedImmune LLC Myeloma May 2014 Early Phase 1
    NCT01264315 Fondazione Neoplasie Sangue Onlus Multiple Myeloma September 2008 Phase 2
    NCT01593410 Celgene Corporation Multiple Myeloma August 2010 Phase 2
    NCT00981708 University of Athens|Hellenic Cooperative Oncology Group Amyloidosis February 2008 Phase 1|Phase 2
    NCT00923663 Medical University of Vienna MALT Lymphoma July 2009 Phase 2
    NCT00179660 Celgene Corporation|Prologue Research International|Celgene Non-Hodgkins Lymphoma August 2005 Phase 2
    NCT01180569 Memorial Sloan Kettering Cancer Center|Celgene Corporation Lymphoma|Follicular Lymphoma August 2010 Phase 1|Phase 2
    NCT01352338 UMC Utrecht|Celgene Corporation Multiple Myeloma August 2011 Phase 1|Phase 2
    NCT01698801 Celgene Corporation Multiple Myeloma October 2012 Phase 2
    NCT00737529 Celgene Mantle Cell Lymphoma December 2008 Phase 2
    NCT01703364 Arbeitsgemeinschaft medikamentoese Tumortherapie|Celgene CLL|Chronic Lymphocytic Leukemia June 2012 Phase 1|Phase 2
    NCT01582776 The Lymphoma Academic Research Organisation Follicular Lymphoma Patients (Phase IB)|Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II) October 2012 Phase 1|Phase 2
    NCT00632359 M.D. Anderson Cancer Center|Celgene Corporation Chronic Lymphocytic Leukemia February 2008 Phase 2
    NCT00478777 Celgene Corporation|Celgene Relapsed or Refractory Multiple Myeloma March 2007 Phase 3
    NCT01460940 Kristie Blum|Celgene|Novartis|Ohio State University Comprehensive Cancer Center Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma October 13, 2011 Phase 2
    NCT01816620 Peking Union Medical College Hospital|Celgene Corporation POEMS Syndrome March 2014 Phase 2
    NCT02371590 University of California, San Diego|Celgene Corporation|Genentech, Inc. Chronic Lymphocytic Leukemia December 2017 Phase 2
    NCT00839059 University of Ulm Acute Myeloid Leukemia January 2009 Phase 1
    NCT01718379 Groupe Francophone des Myelodysplasies|Celgene|Roche Pharma AG Myelodysplastic Syndromes July 2010 Phase 2
    NCT02538965 Celgene Leukemia, Myeloid November 19, 2015 Phase 2
    NCT01723839 Hackensack University Medical Center|Celgene Corporation Chronic Lymphocytic Leukemia (CLL) September 2011 Phase 2
    NCT00923234 Technische Universität Dresden|Celgene Corporation Myelodysplastic Syndromes|Acute Myelogenous Leukemia June 2009 Phase 1
    NCT00933426 M.D. Anderson Cancer Center|Celgene Corporation Prostate Cancer August 2009 Phase 1
    NCT00840827 Weill Medical College of Cornell University|Celgene Corporation Myelodysplastic Syndrome December 2008 Phase 2
    NCT01553786 The Lymphoma Academic Research Organisation T-cell Lymphoma November 2011 Phase 2
    NCT00543114 Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Celgene Corporation Chronic Lymphocytic Leukemia|Small Lymphocytic Leukemia October 2007 Phase 1
    NCT01615042 University of California, Davis|Celgene Acute Leukemia August 2012 Phase 1
    NCT01254578 National Cancer Institute (NCI) Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A|Adult Acute Promyelocytic Leukemia With PML-RARA|Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-Cell Lymphoma|Alkylating Agent-Related Acute Myeloid Leukemia|A November 2010 Phase 1
    NCT01011894 Memorial Sloan Kettering Cancer Center|Celgene Corporation Chronic Lymphocytic Leukemia|Leukemia November 6, 2009 Phase 2
    NCT01032291 Celgene Corporation|Celgene Colorectal Cancer December 2009 Phase 2
    NCT01002703 University of Leipzig|Celgene Corporation|Mundipharma Pte Ltd.|Amgen Multiple Myeloma September 2009 Phase 1|Phase 2
    NCT00675441 M.D. Anderson Cancer Center|Celgene Corporation Graft-versus-Host Disease April 2008 Phase 2
    NCT01611259 Arbeitsgemeinschaft medikamentoese Tumortherapie Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) May 2012 Phase 2
    NCT01996865 Celgene Lymphoma, Non-Hodgkin April 2, 2014 Phase 3
    NCT01947309 Celgene Multiple Myeloma November 2013
    NCT00535873 M.D. Anderson Cancer Center|Celgene Corporation Leukemia|CLL|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma October 2007 Phase 2
    NCT00294632 M.D. Anderson Cancer Center|Celgene Corporation Lymphoma February 2006 Phase 1|Phase 2
    NCT00065156 Celgene Corporation|Celgene Myelodysplastic Syndromes June 2003 Phase 2
    NCT01766583 The Lymphoma Academic Research Organisation|Celgene Corporation Relapsed/Refractory B-cell Lymphoma February 2013 Phase 1
    NCT01316523 University of California, Davis|Celgene Non Hodgkin's Lymphoma December 2010 Phase 2
    NCT02354313 Fondazione Italiana Linfomi ONLUS MANTLE CELL LYMPHOMA May 2010 Phase 3
    NCT00671801 M.D. Anderson Cancer Center|Celgene Corporation Malignant Gliomas April 2008 Phase 1
    NCT01919619 M.D. Anderson Cancer Center Blood And Marrow Transplantation|Leukemia|Lymphoma November 2013 Early Phase 1
    NCT00466895 Leslie Andritsos|Celgene Corporation|Ohio State University Comprehensive Cancer Center Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Chronic Lymphocytic Leukemia April 2007 Phase 1
    NCT01463670 Memorial Sloan Kettering Cancer Center|Montefiore Medical Center|State University of New York - Downstate Medical Center|University of Rochester|Weill Medical College of Cornell University|Stamford Hospital|Columbia University|State University of New York - Upstate Medical University Multiple Myeloma October 2011 Phase 2
    NCT00434239 Peter MacCallum Cancer Centre, Australia|Celgene Corporation Myelodysplasia February 2007 Early Phase 1
    NCT00966693 M.D. Anderson Cancer Center|Celgene Myeloma August 2009 Phase 1|Phase 2
    NCT02963610 Fox Chase Cancer Center|Merck Sharp & Dohme Corp.|Celgene Relapsed or Refractory Solid Tumors|Nonsmall Cell Lung Cancer March 29, 2017 Phase 1|Phase 2
    NCT00413036 Celgene Lymphoma, Non-Hodgkin's June 2006 Phase 2
    NCT02225275 M.D. Anderson Cancer Center|Genentech, Inc.|Celgene Corporation Leukemia March 31, 2016 Phase 2
    NCT00971685 Istituto Clinico Humanitas POEMS Syndrome July 2009 Phase 2
    NCT00720850 Technische Universität Dresden|Celgene Corporation Myelodysplastic Syndromes|Acute Myelogenous Leukemia April 2008 Phase 2
    NCT01651039 Ajai Chari|Novartis Pharmaceuticals|Icahn School of Medicine at Mount Sinai Multiple Myeloma July 2012 Phase 2
    NCT00778752 Universitätsklinikum Hamburg-Eppendorf Multiple Myeloma April 2009 Phase 1|Phase 2
    NCT00179647 Celgene Corporation|Prologue Research International|Celgene Multiple Myeloma September 2005 Phase 3
    NCT01081431 Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH|ClinAssess GmbH Myelodysplastic Syndromes March 2010 Phase 2
    NCT00267059 M.D. Anderson Cancer Center|Celgene Corporation Chronic Lymphocytic Leukemia|Leukemia December 2005 Phase 2
    NCT02312102 Massachusetts General Hospital|Celgene Corporation|Millennium Pharmaceuticals, Inc. Myelodysplastic Syndrome|Acute Myeloid Leukemia March 2015 Phase 1
    NCT01133743 University Health Network, Toronto|Celgene Corporation Chronic Lymphocytic Leukemia May 2010 Phase 2
    NCT00420849 Celgene Corporation|Celgene Multiple Myeloma November 2006 Phase 3
    NCT02255162 Massachusetts General Hospital|Celgene Corporation Acute Myeloid Leukemia (AML)|Acute Myelocytic Leukemia|Acute Myelogenous Leukemia|Acute Granulocytic Leukemia|Acute Non-Lymphocytic Leukemia January 2015 Phase 1
    NCT00622336 Celgene Corporation|Celgene Multiple Myeloma December 2003 Phase 3
    NCT00996931 Sutter Medical Foundation Autism February 2009 Phase 2
    NCT02322320 National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program Multiple Myeloma March 2015 Phase 3
    NCT01956695 Institut Curie|Centre Hospitalier Universitaire, Amiens|Institut Bergonié|University Hospital, Clermont-Ferrand|University Hospital, Lille|Central Hospital, Nancy, France|Groupe Hospitalier Pitie-Salpetriere|Centre Henri Becquerel|University Hospital, Tours|Centre Leon Berard|University Hospital, Grenoble Lymphoma|Relapse September 2013 Phase 2
    NCT01207921 Washington University School of Medicine|Celgene Corporation Hodgkin Disease April 28, 2011 Phase 1
    NCT00179621 Celgene Corporation|ICON Clinical Research|Celgene Myelodysplastic Syndromes July 2005 Phase 3
    NCT01029262 Celgene Anemia January 26, 2010 Phase 3
    NCT00109772 Celgene Corporation|Celgene Complex Regional Pain Syndrome, Type I February 2005 Phase 2
    NCT00619684 Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma February 2008 Phase 2
    NCT00885508 Groupe Francophone des Myelodysplasies|Celgene Corporation Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Acute Myeloid Leukemia February 2009 Phase 2
    NCT01034592 Jason Robert Gotlib|Celgene Corporation|Stanford University Anemia|Leukemia|Acute Myeloid Leukemia (AML)|Myelodysplastic Syndromes (MDS) November 2009
    NCT01142232 Attaya Suvannasankha|Celgene|Indiana University Multiple Myeloma August 27, 2010 Phase 1|Phase 2
    NCT00352001 Mikkael Sekeres MD|National Cancer Institute (NCI)|Case Comprehensive Cancer Center Leukemia|Myelodysplastic Syndromes May 2006 Phase 1|Phase 2
    NCT00928486 Celgene Corporation Multiple Myeloma April 2009 Phase 3
    NCT02523040 Dana-Farber Cancer Institute|Celgene Langerhans Cell Histiocytosis (LCH)|Histiocytoses Erdheim-chester Disease|Histiocytic Sarcoma (HS) August 2015 Phase 2
    NCT01995669 M.D. Anderson Cancer Center|Celgene|Genentech, Inc. Lymphoma May 2014 Phase 1|Phase 2
    NCT01421927 University Hospital, Bordeaux Multiple Myeloma August 2011 Phase 1
    NCT01433965 University of California, Davis|Celgene Acute Myeloid Leukemia|Myelodysplastic Syndrome August 2012 Phase 1
    NCT00901615 Lymphoma Study Association Lymphoma, Large B-Cell, Diffuse|Follicular Lymphoma|Mantle Cell Lymphoma|Marginal Zone B-Cell Lymphoma January 2009 Phase 1|Phase 2
    NCT01373229 David Rizzieri, MD|Celgene Corporation|Genzyme, a Sanofi Company|Duke University Leukemia, Lymphocytic, Chronic, B-Cell January 2012 Phase 1
    NCT00972842 Arbeitsgemeinschaft medikamentoese Tumortherapie|Merck Sharp & Dohme Corp.|Celgene Corporation Peripheral T-Cell Non-Hodgkin's Lymphoma September 2009 Phase 1|Phase 2
    NCT01036399 University of Bologna Peripheral T-cell Lymphoma November 2008 Phase 2
    NCT01021423 Celgene Corporation|Celgene Mantle Cell Lymphoma|Non-Hodgkin's Lymphoma April 2010 Phase 3
    NCT00963534 Lund University Hospital|Mundipharma Pte Ltd.|Celgene|Roche Pharma AG Mantle Cell Lymphoma September 2009 Phase 1|Phase 2
    NCT00430365 University Hospital, Toulouse|Intergroupe Francophone du Myelome|Celgene Myeloma June 2006 Phase 3
    NCT01459211 University College, London Chronic Lymphocytic Leukemia May 2012 Phase 2
    NCT02692339 Celgene Multiple Myeloma February 2016
    NCT02871219 M.D. Anderson Cancer Center|Genentech, Inc. Follicular Lymphoma December 6, 2016 Phase 2
    NCT01673308 Ulsan University Hospital|Cooperative Study Group A for Hematology Myelodysplastic Syndrome August 2012 Phase 2
    NCT01111903 ARCAGY/ GINECO GROUP Ovarian Cancer Recurrent May 2009 Phase 1|Phase 2
    NCT00412581 M.D. Anderson Cancer Center|Celgene Corporation Melanoma September 2005 Phase 1
    NCT01718743 M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Myeloma December 2012 Phase 2
    NCT00165477 Dana-Farber Cancer Institute|Celgene Corporation|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Massachusetts General Hospital|University of Virginia Glioblastoma|Gliosarcoma|Malignant Gliomas September 2005 Phase 2
    NCT00633945 University of Pennsylvania|Celgene Corporation Cutaneous Lupus Erythematosus (CLE) November 2007
    NCT00352365 National Cancer Institute (NCI) Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia Wit June 2006 Phase 2
    NCT01744912 TG Therapeutics, Inc. Non-Hodgkins Lymphoma|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|B-cell Lymphomas|Marginal Zone Lymphoma|Mantle Cell Lymphoma|Waldenstrom's Macroglobulinemia December 2012 Phase 1|Phase 2
    NCT01583283 Celgene Multiple Myeloma July 12, 2012 Phase 1|Phase 2
    NCT01830478 Gruppo Italiano Studio Linfomi Indolent Non Hodgkin Lymphoma April 2009 Phase 2
    NCT01578954 UNC Lineberger Comprehensive Cancer Center|Celgene Acute Myeloid Leukemia June 2012 Phase 1
    NCT00540007 Washington University School of Medicine|Celgene Corporation Hodgkin Disease September 6, 2007 Phase 2
    NCT01282047 French National Agency for Research on AIDS and Viral Hepatitis|Celgene Corporation|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) HIV Infection Associated Kaposi Disease October 2011 Phase 2
    NCT01530594 King Faisal Specialist Hospital & Research Center Multiple Myeloma January 2009 Phase 3
    NCT00104962 National Cancer Institute (NCI) Childhood Myelodysplastic Syndromes|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Refractory Anemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Ringed Sideroblasts|Refractory Cytopenia With Multilineage Dysplasia|Secondary Myelodysplastic Syndromes|Unspecified Childhood Solid Tumor, Protocol Specific March 2005 Phase 1
    NCT01243476 Fundación General de la Universidad de Salamanca|Celgene Corporation Myelodysplastic Syndrome January 2010 Phase 3
    NCT01002755 M.D. Anderson Cancer Center|GlaxoSmithKline|Celgene Corporation Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma January 2010 Phase 2
    NCT01133275 H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation Myelodysplastic Syndrome|MDS April 2010 Phase 2
    NCT00287287 Kenneth Ain|Celgene Corporation|University of Kentucky Thyroid Neoplasms February 2006 Phase 2
    NCT00684242 M.D. Anderson Cancer Center|Celgene Corporation Advanced Cancer|Pain May 2008 Phase 2
    NCT00403169 The Cleveland Clinic|National Cancer Institute (NCI) Kidney Cancer August 2004 Phase 2
    NCT01556776 German CLL Study Group|Celgene Chronic Lymphocytic Leukemia July 2012 Phase 3
    NCT01054196 Weill Medical College of Cornell University|Celgene Multiple Myeloma August 2010 Phase 1|Phase 2
    NCT01600053 Thomas Kipps|Celgene Corporation|University of California, San Diego Chronic Lymphocytic Leukemia November 2011 Phase 2
    NCT00891384 Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH Multiple Myeloma April 1, 2009 Phase 3
    NCT00609869 H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation Lymphocytic Leukemia|Mantle Cell Lymphoma October 2007 Phase 2
    NCT02875067 New York University School of Medicine|Merck Sharp & Dohme Corp. Relapsed Hodgkin Lymphoma|Relapsed Non-Hodgkin Lymphoma August 2016 Phase 1|Phase 2
    NCT02200848 Georgetown University|National Cancer Institute (NCI) Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma April 2014 Phase 1
    NCT02898259 Case Comprehensive Cancer Center B Cell Lymphoma|Lymphoma February 20, 2017 Phase 1|Phase 2
    NCT01373294 H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation Bladder Cancer November 30, 2011 Phase 2
    NCT00717756 Brown University|Memorial Hospital of Rhode Island|Roger Williams Medical Center Liver Cancer January 2009 Phase 2
    NCT00774345 Celgene B-cell Chronic Lymphocytic Leukemia January 27, 2009 Phase 3
    NCT01985477 M.D. Anderson Cancer Center|Celgene Corporation Myeloma December 2013 Phase 1
    NCT00975806 Celgene Renal Cell Carcinoma September 2009 Phase 1|Phase 2
    NCT01218555 Emory University|Celgene|Novartis Solid Organ Malignancies|Adenoidcystic Carcinoma|Neuroendocrine Tumors September 2010 Phase 1
    NCT01122472 The Lymphoma Academic Research Organisation Lymphoma|Diffuse Large B-cell Lymphoma April 2009 Phase 3
    NCT00765245 Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) Lymphoma October 2008 Phase 2
    NCT01079936 M.D. Anderson Cancer Center Myeloma|Stem Cell Transplantation March 2010 Phase 1|Phase 2
    NCT01088373 Groupe Francophone des Myelodysplasies|Celgene Corporation Myelodysplastic Syndromes March 2010 Phase 2
    NCT03106324 Celgene Multiple Myeloma March 31, 2017
    NCT00883623 Heidelberg University|Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH Primary Amyloidosis April 2009 Phase 2
    NCT01307605 Swiss Group for Clinical Cancer Research Lymphoma February 9, 2011 Phase 2
    NCT02659293 University of Chicago Multiple Myeloma April 2016 Phase 3
    NCT03113695 University of California, San Diego Richter's Syndrome|CLL August 2017 Phase 1
    NCT00759603 M.D. Anderson Cancer Center|Celgene Corporation Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma September 2008 Phase 2
    NCT00988208 Celgene Prostate Cancer November 11, 2009 Phase 3
    NCT00744536 Sunnybrook Health Sciences Centre|Celgene Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic|Angiogenesis January 2008 Phase 2
    NCT00633594 SCRI Development Innovations, LLC|Millennium Pharmaceuticals, Inc.|Celgene Mantle Cell Lymphoma June 2008 Phase 1|Phase 2
    NCT01729104 M.D. Anderson Cancer Center|Celgene|Onyx Therapeutics, Inc. Lymphoma April 25, 2013 Phase 1|Phase 2
    NCT00910910 Celgene B-Cell Chronic Lymphocytic Leukemia (B-CLL) October 2009 Phase 3
    NCT01403246 Gruppo Italiano Malattie EMatologiche dell'Adulto Chronic Lymphocytic Leukemia November 2011 Phase 1|Phase 2
    NCT02077959 Yvonne Efebera|CureTech Ltd|Ohio State University Comprehensive Cancer Center Multiple Myeloma March 3, 2014 Phase 1|Phase 2
    NCT02041325 Boston VA Research Institute, Inc.|Dana-Farber Cancer Institute Plasma Cell Disorder April 2005 Phase 2
    NCT01465230 Yale University|Celgene Corporation Chronic Lymphocytic Leukemia March 2012 Phase 2
    NCT01127542 The Christie NHS Foundation Trust|Celgene Corporation|Leukemia Research Fund Chronic Lymphocytic Leukaemia May 2010 Phase 2
    NCT01838434 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Celgene Corporation|Gilead Sciences|Biologics, Inc. Relapsed/Refractory Mantle Cell Lymphoma July 2013 Phase 1|Phase 2
    NCT01222195 M.D. Anderson Cancer Center|Celgene Corporation Leukemia February 2008 Phase 2
    NCT02272803 Bristol-Myers Squibb|AbbVie Multiple Myeloma January 22, 2015 Phase 2
    NCT01556035 University Hospital, Bordeaux Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type) July 2012 Phase 2
    NCT03110822 Oncotherapeutics|Incyte Corporation Multiple Myeloma February 6, 2017 Phase 1
    NCT00977132 Heinrich-Heine University, Duesseldorf Myelodysplastic Syndrome MDS October 2009 Phase 2
    NCT01704781 Bionor Immuno AS|Celgene Corporation HIV-1 Infection September 2012 Phase 1|Phase 2
    NCT01558167 German CLL Study Group|Mundipharma Research GmbH & Co KG|Roche Pharma AG|Celgene Chronic Lymphocytic Leukemia February 2011 Phase 1|Phase 2
    NCT02369367 M.D. Anderson Cancer Center|Celgene Corporation Malignant Gliomas April 2008 Phase 2
    NCT01358734 Celgene Acute Myeloid Leukemia|Acute Myelogenous Leukemia April 2012 Phase 2
    NCT01755975 Memorial Sloan Kettering Cancer Center|Saint Francis/Mount Sinai Regional Cancer Center|Weill Medical College of Cornell University|University of Nebraska|Celgene Corporation|Biologics, Inc. Multiple Myeloma|Non-Hodgkin's Lymphoma December 2012 Phase 1|Phase 2
    NCT02589145 M.D. Anderson Cancer Center|Celgene Corporation Lymphoma June 2016 Phase 1|Phase 2
    NCT01886859 National Cancer Institute (NCI) B-Cell Prolymphocytic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma April 26, 2013 Phase 1
    NCT01246076 Washington University School of Medicine Myelodysplastic Syndromes June 2011 Phase 2
    NCT01419795 Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Prolymphocytic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse May 2012 Phase 2
    NCT02030483 Weill Medical College of Cornell University|Celgene Corporation|Pfizer Multiple Myeloma February 2014 Phase 1
    NCT01555281 Swiss Group for Clinical Cancer Research Multiple Myeloma April 2012 Phase 1|Phase 2
    NCT01109004 National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI) Multiple Myeloma May 2010 Phase 3
    NCT01246557 Hospital Universitari Vall d'Hebron Research Institute Chronic Lymphatic Leukemia December 2009 Phase 1|Phase 2
    NCT00837031 SCRI Development Innovations, LLC|Celgene Corporation Metastatic Pancreatic Cancer February 2009 Phase 2
    NCT01090089 Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH|ClinAssess GmbH Multiple Myeloma March 1, 2010 Phase 3
    NCT01254617 National Cancer Institute (NCI) Recurrent Colon Carcinoma|Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Laryngeal Verrucous Carcinoma|Recurrent Lip and Oral Cavity Squamous Cell Carcinoma|Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary|Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma|Recurrent Oral Cavity Verrucous Carcinoma|Recurrent Oropharyngeal Squamous Cell C February 10, 2011 Phase 1
    NCT01553149 National Cancer Institute (NCI) Neurofibromatosis Type 1|Recurrent Childhood Pilocytic Astrocytoma|Recurrent Childhood Visual Pathway Glioma March 19, 2012 Phase 2
    NCT00848328 University of California, Davis|Celgene Lymphoma March 2008 Phase 2
    NCT00546897 Washington University School of Medicine Leukemia, Myeloid, Acute February 2007 Phase 2
    NCT00738829 Arbeitsgemeinschaft medikamentoese Tumortherapie|Celgene Corporation|Roche Pharma AG Leukemia, Lymphocytic, Chronic, B-Cell October 2008 Phase 1|Phase 2
    NCT02038153 Albert Einstein College of Medicine, Inc.|National Cancer Institute (NCI) Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Acute Megakaryoblastic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With Maturation|Adult Acute Myeloid Leukemia With Minimal Differentiation|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); R December 2013 Phase 1|Phase 2
    NCT01116193 Institut de Cancérologie de la Loire|Celgene Corporation Leukemia, Lymphoid|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma January 2010 Phase 2
    NCT00875667 Celgene Mantle Cell Lymphoma|Lymphoma, Mantle-Cell April 2009 Phase 2
    NCT00424047 Celgene Corporation|Celgene Multiple Myeloma September 2003 Phase 3
    NCT01062152 Telik Myelodysplastic Syndrome November 2009 Phase 1
    NCT01408199 Hospital Universitari Vall d'Hebron Research Institute Cutaneous Lupus January 2010 Phase 4
    NCT01400685 Massachusetts General Hospital|Dana-Farber Cancer Institute Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|B Chronic Lymphocytic Leukemia December 2012 Phase 1
    NCT01924169 M.D. Anderson Cancer Center|Celgene Corporation Hematologic Disorder November 24, 2014 Phase 2
    NCT01378091 Columbia University|Celgene Corporation Prostate Cancer August 2005 Phase 1
    NCT00735930 National Cancer Institute (NCI) Anemia|Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Thrombocytopenia August 2008 Phase 1
    NCT02471820 Meletios A. Dimopoulos|University of Athens Multiple Myeloma November 2014 Phase 2
    NCT01133665 University of Chicago|Celgene Corporation Squamous Cell Carcinoma February 2010 Phase 2
    NCT01604031 Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital System B-cell Chronic Lymphocytic Leukemia February 2013 Phase 1
    NCT00729118 Ohio State University Comprehensive Cancer Center|Merck Sharp & Dohme Corp. Multiple Myeloma|Plasma Cell Neoplasm September 26, 2008 Phase 1
    NCT02472691 Heinrich-Heine University, Duesseldorf|Celgene Corporation Leukemia, Myeloid, Acute|Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic June 2015 Phase 2
    NCT01927718 M.D. Anderson Cancer Center|Celgene Corporation Myeloma January 2014
    NCT00096044 Roswell Park Cancer Institute|Celgene Leukemia March 2004 Phase 2
    NCT00829647 Scripps Health|Bristol-Myers Squibb|Celgene Corporation Chronic Lymphocytic Leukemia|Leukemia January 2009 Phase 1|Phase 2
    NCT01401322 Stanford University|Celgene Corporation Leukemia|Relapsed Adult Acute Lymphocytic Leukemia January 2011 Phase 2
    NCT01553357 IRCCS Centro di Riferimento Oncologico della Basilicata|Celgene Corporation Primary Plasma Cell Leukemia March 2009 Phase 2
    NCT01788189 University Hospital, Essen|Celgene B-cell Lymphoma January 2013 Phase 1|Phase 2
    NCT01003769 Mayo Clinic|National Cancer Institute (NCI) Recurrent Chronic Lymphocytic Leukemia September 2013 Phase 1|Phase 2
    NCT01375140 M.D. Anderson Cancer Center|Incyte Corporation Myeloproliferative Diseases September 2011 Phase 2
    NCT02538198 Memorial Sloan Kettering Cancer Center Plasma Cell Myeloma August 31, 2015 Phase 2
    NCT01542918 University of California, San Francisco|Celgene Corporation|Genentech, Inc. Recurrent/Refractory CNS|Intraocular Lymphoma December 2012 Phase 1
    NCT01556477 Nordic MDS Group Myelodysplastic Syndrome|Acute Myelogenous Leukemia March 2012 Phase 2
    NCT00890929 Stanford University|Celgene Corporation Acute Myeloid Leukemia (AML)|Adult Acute Myeloblastic Leukemia April 2009 Phase 1|Phase 2
    NCT01202890 New Mexico Cancer Care Alliance|Celgene Corporation Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma September 2010 Phase 1
    NCT02145598 Lars-Olof Muegge|University of Jena Multiple Myeloma August 2013 Phase 2|Phase 3
    NCT02348528 Celgene Corporation Multiple Myeloma September 2012 Phase 2
    NCT01246622 Roswell Park Cancer Institute|National Cancer Institute (NCI)|Celgene Corporation Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia February 7, 2011 Phase 1
    NCT00091260 Vaishali Sanchorawala|Celgene Corporation|Boston Medical Center Multiple Myeloma January 2004 Phase 2
    NCT02906332 Hackensack University Medical Center Multiple Myeloma December 2016 Phase 2
    NCT00665652 Dartmouth-Hitchcock Medical Center|Celgene Corporation Neuropathy|Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS) April 2008 Phase 2
    NCT01472562 Weill Medical College of Cornell University|Celgene Mantle Cell Lymphoma June 2011 Phase 2
    NCT00689936 Celgene Corporation Multiple Myeloma August 2008 Phase 3
    NCT01904643 Stanford University|National Cancer Institute (NCI) Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adul February 2014 Phase 1
    NCT00786851 Fondazione Italiana Linfomi ONLUS|Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte MANTLE CELL LYMPHOMA July 2008 Phase 2
    NCT01093183 University of Nebraska|National Cancer Institute (NCI) Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer March 2010 Phase 1|Phase 2
    NCT00142168 Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Celgene Corporation|Genentech, Inc. Waldenstrom's Macroglobulinemia September 2004 Phase 2
    NCT02529852 M.D. Anderson Cancer Center|Celgene|Genentech, Inc. Lymphoma November 4, 2015 Phase 1|Phase 2
    NCT01098656 European Organisation for Research and Treatment of Cancer - EORTC Lymphoma July 2010 Phase 3
    NCT00828802 Duke University|Celgene Corporation Myelodysplastic Syndromes March 2009 Phase 1
    NCT00963105 Celgene Relapsed or Refractory Chronic Lymphocytic Leukemia October 19, 2009 Phase 2
    NCT02521714 Celgene Corporation Healthy Volunteers August 2015 Phase 1
    NCT00840931 H. Lee Moffitt Cancer Center and Research Institute|Celgene Leukemia February 2, 2009 Phase 1
    NCT00603447 Amgen Relapsed Multiple Myeloma May 2008 Phase 1
    NCT02918331 Janssen Pharmaceutical K.K. Multiple Myeloma September 27, 2016 Phase 1
    NCT01132586 National Cancer Institute (NCI) Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA|Alkylating Agent-Related Acute Myeloid Leukemia|de Novo Myelodysplastic Syndrome|Previously Treated Myel May 2010 Phase 1
    NCT01442714 Stanford University|Celgene Corporation Leukemia|Acute Myeloid Leukemia (AML)|Myelodysplastic Syndromes (MDS) August 2011 Phase 2
    NCT01702831 University Health Network, Toronto|Princess Margaret Hospital, Canada|Otsuka Pharmaceutical Development & Commercialization, Inc.|Celgene Corporation Multiple Myeloma March 2013 Phase 2
    NCT02399085 MorphoSys AG Diffuse Large B-cell Lymphoma December 2015 Phase 2
    NCT01938001 Celgene Lymphoma, Non-Hodgkin November 21, 2013 Phase 3
    NCT02075021 New York University School of Medicine|Celgene Corporation Relapsed or Refractory Multiple Myeloma March 2014 Phase 1|Phase 2
    NCT02955823 Fondazione Italiana Linfomi ONLUS Diffuse Large B-cells Non-Hodgkin Lymphoma September 2016 Phase 2
    NCT00227591 National Cancer Institute (NCI) Essential Thrombocythemia|Polycythemia Vera|Primary Myelofibrosis December 2005 Phase 2
    NCT01178814 Columbia University|Celgene Corporation Myelodysplastic Syndrome July 2010 Phase 2
    NCT02160015 National Cancer Institute (NCI) Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Small Lymphocytic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Small Lymphocytic Lymphoma May 9, 2014 Phase 1
    NCT02112175 Celgene Corporation Multiple Myeloma April 2014 Phase 3
    NCT02193698 Chiba University POEMS Syndrome July 2014 Phase 2
    NCT01429025 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Celgene Corporation Refractory/Relapsed Indolent Non-Hodgkin Lymphoma May 2012 Phase 1
    NCT01029054 University of Michigan Cancer Center|Onyx Therapeutics, Inc.|Celgene Multiple Myeloma September 2009 Phase 1|Phase 2
    NCT03184194 VU University Medical Center|Erasmus Medical Center|UMC Utrecht|Maastricht University Medical Center|Meander ziekenhuis|Antonius Ziekenhuis|Isala|Albert Schweitzer ziekenhuis|University Medical Center Radboud|University Medical Center Groningen|Rijnstate ziekenhuis Myeloma July 15, 2017 Phase 2
    NCT01222754 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Diffuse Intrinsic Pontine Glioma|Anaplastic Astrocytoma|High Grade Glioma September 30, 2010 Phase 1
    NCT00890552 Stanford University|Celgene Corporation Leukemia|Amyloidosis April 2009
    NCT00903630 Masonic Cancer Center, University of Minnesota|Celgene Corporation Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer April 2009 Phase 1|Phase 2
    NCT02917941 Takeda Relapsed and/or Refractory Multiple Myeloma September 23, 2016 Phase 2
    NCT01038388 Emory University|Merck Sharp & Dohme Corp.|Celgene Corporation Multiple Myeloma January 15, 2010 Phase 1
    NCT02086604 Washington University School of Medicine Lymphoma, Large B-Cell, Diffuse September 18, 2014 Phase 1
    NCT00046735 Celgene Corporation Neoplasms June 2002 Phase 1
    NCT00968331 University of Bologna Diffuse Large B-cell Lymphoma March 2009 Phase 2
    NCT01712828 Celgene Corporation|Covance Healthy October 2012 Phase 1
    NCT00410605 National Cancer Institute (NCI) Refractory Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma November 2006 Phase 2
    NCT01779167 Weill Medical College of Cornell University|Celgene Corporation Waldenstrom Macroglobulinemia June 2012 Phase 2
    NCT01939327 Institut Paoli-Calmettes Non-Hodgkin Lymphoma September 2013 Phase 2
    NCT00398515 National Cancer Institute (NCI) Refractory Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma March 2007 Phase 1
    NCT01116154 City of Hope Medical Center Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-Cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell May 2010 Phase 1
    NCT00691704 Cristina Gasparetto|Celgene Corporation|Duke University Multiple Myeloma August 2008 Phase 2
    NCT02005289 Ohio State University Comprehensive Cancer Center|MorphoSys AG Contiguous Stage II Small Lymphocytic Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Prolymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage I Small Lymphocytic Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage III Small Lymphocytic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Small Lymphocytic Lymphoma December 23, 2013 Phase 2
    NCT00352794 M.D. Anderson Cancer Center|Celgene Corporation Myelofibrosis July 2006 Phase 2
    NCT01440582 M.D. Anderson Cancer Center|Novartis Myeloma February 18, 2013 Phase 1
    NCT02532257 M.D. Anderson Cancer Center|Janssen, LP Lymphoma|Follicular Lymphoma (FL) April 2016 Phase 2
    NCT01829568 National Cancer Institute (NCI)|Celgene Corporation CD20 Positive|Stage II Grade 1 Contiguous Follicular Lymphoma|Stage II Grade 1 Non-Contiguous Follicular Lymphoma|Stage II Grade 2 Contiguous Follicular Lymphoma|Stage II Grade 2 Non-Contiguous Follicular Lymphoma|Stage II Grade 3 Contiguous Follicular Lymphoma|Stage II Grade 3 Non-Contiguous Follicular Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphom June 21, 2013 Phase 1
    NCT01644799 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Gilead Sciences|Celgene Corporation Recurrent Follicular Lymphoma July 2013 Phase 1
    NCT00729638 Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Mayo Clinic|Memorial Sloan Kettering Cancer Center|Medical College of Wisconsin Multiple Myeloma June 2008 Phase 1
    NCT02334865 Roswell Park Cancer Institute|National Cancer Institute (NCI)|Celgene Partial Response of Multiple Myeloma or Plasma Cell Leukemia|Plasma Cell Myeloma March 9, 2016 Phase 1
    NCT01297764 Hackensack University Medical Center Multiple Myeloma April 2011 Phase 1|Phase 2
    NCT01639898 University Hospital, Limoges|Ministry of Health, France|Celgene Corporation POEMS Syndrome July 2012 Phase 2
    NCT01347944 Celgene Corporation Myelodysplastic Syndrome January 2011
    NCT02086552 Mayo Clinic|National Cancer Institute (NCI)|Novartis Pharmaceuticals Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma January 2014 Phase 2
    NCT01127386 Cantonal Hospital of St. Gallen|Celgene Corporation Cancer Cachexia Syndrome May 2010 Phase 1|Phase 2
    NCT02232516 Northwestern University|Celgene|National Cancer Institute (NCI) Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Peripheral T-cell Lymphoma|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IA Mycosis Fungoides/Sezary Syndrome|Stage IB Mycosis Fungoides/Sezary Syndrome|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IIA Mycosis Fungoides/Sezary Syndrome|Stage IIB Mycosis Fungoides/Sezary Syndrome|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IIIA Myco June 2015 Phase 2
    NCT00466921 Northwestern University|National Cancer Institute (NCI) Lymphoma February 2005 Phase 2
    NCT00843882 National Cancer Institute (NCI) Anemia|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome January 29, 2009 Phase 3
    NCT02420860 M.D. Anderson Cancer Center|Bristol-Myers Squibb Myeloma April 2015 Phase 2
    NCT01772420 Albert Einstein College of Medicine, Inc.|National Cancer Institute (NCI) Adult Myelodysplastic Syndrome|Anemia|Chronic Myelomonocytic Leukemia October 2012 Phase 2
    NCT01402284 National Cancer Institute (NCI)|Celgene|Onyx Therapeutics, Inc.|National Institutes of Health Clinical Center (CC) Multiple Myeloma July 21, 2011 Phase 2
    NCT01446133 M.D. Anderson Cancer Center|Celgene Corporation Leukemia|Lymphoma December 12, 2011 Phase 2
    NCT00553644 National Cancer Institute (NCI) Recurrent Mantle Cell Lymphoma November 2007 Phase 2
    NCT01737177 Fondazione Italiana Linfomi ONLUS Mantle Cell Lymphoma April 2012 Phase 2
    NCT00580242 Massachusetts General Hospital|Celgene Corporation|Dana-Farber Cancer Institute Myelodysplasia November 2007 Phase 1
    NCT00831766 H. Lee Moffitt Cancer Center and Research Institute|Celgene Myelodysplastic Syndrome|Acute Myeloid Leukemia January 22, 2009 Phase 1|Phase 2
    NCT01675141 National Cancer Institute (NCI)|Celgene Corporation|National Institutes of Health Clinical Center (CC) Multiple Myeloma August 20, 2012 Phase 2
    NCT00100880 National Cancer Institute (NCI) Childhood Atypical Teratoid/Rhabdoid Tumor|Childhood Central Nervous System Germ Cell Tumor|Childhood Choroid Plexus Tumor|Childhood Craniopharyngioma|Childhood Ependymoblastoma|Childhood Grade I Meningioma|Childhood Grade II Meningioma|Childhood Grade III Meningioma|Childhood High-grade Cerebellar Astrocytoma|Childhood High-grade Cerebral Astrocytoma|Childhood Infratentorial Ependymoma|Childhood Low-grade Cerebellar Astrocytoma|Childhood Low-grade Cerebral Astrocytoma|Childhood Medulloepithelio November 2004 Phase 1
    NCT02636322 M.D. Anderson Cancer Center|Celgene|Janssen Scientific Affairs, LLC Lymphoma March 2016 Phase 2
    NCT01348503 Indiana University School of Medicine|Celgene Corporation|Indiana University Hepatocellular Carcinoma May 2011 Phase 1
    NCT01348919 Cephalon|Teva Pharmaceutical Industries Multiple Myeloma August 2011 Phase 1|Phase 2
    NCT01271283 National Cancer Institute (NCI) Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia December 2010 Phase 2
    NCT01076543 National Cancer Institute (NCI) AIDS-Related Hodgkin Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Waldenstrom Macroglobulinemia April 15, 2010 Phase 1|Phase 2
    NCT02655458 Hearn Jay Cho|Bristol-Myers Squibb|Icahn School of Medicine at Mount Sinai Multiple Myeloma January 2016 Phase 1
    NCT01936532 Nantes University Hospital Newly Diagnosed Multiple Myeloma November 12, 2014 Phase 2
    NCT00502112 Seattle Genetics, Inc. Myelodysplastic Syndrome (MDS) March 2008 Phase 1
    NCT00695786 M.D. Anderson Cancer Center|Celgene Lymphoma June 2008 Phase 2
    NCT01200004 M.D. Anderson Cancer Center|Yukiguni Maitake Company Ltd. Advanced Cancers April 2012 Phase 1
    NCT01145495 National Cancer Institute (NCI) Stage II Grade 1 Contiguous Follicular Lymphoma|Stage II Grade 1 Non-Contiguous Follicular Lymphoma|Stage II Grade 2 Contiguous Follicular Lymphoma|Stage II Grade 2 Non-Contiguous Follicular Lymphoma|Stage II Grade 3 Contiguous Follicular Lymphoma|Stage II Grade 3 Non-Contiguous Follicular Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Gra June 15, 2010 Phase 2
    NCT03015896 Kami Maddocks|Bristol-Myers Squibb|Ohio State University Comprehensive Cancer Center Grade 3a Follicular Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Waldenstrom Macroglobulinemia|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle C February 14, 2017 Phase 1|Phase 2
    NCT03191981 University of Leeds|Myeloma UK|Karyopharm Therapeutics Inc Myeloma Multiple September 1, 2017 Phase 1|Phase 2
    NCT02568553 National Cancer Institute (NCI) B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma|CD19 Positive|Mediastinal Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma June 14, 2016 Phase 1
    NCT01955499 National Cancer Institute (NCI) Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma September 13, 2013 Phase 1
    NCT01476787 Celgene|The Lymphoma Academic Research Organisation Follicular Lymphoma December 29, 2011 Phase 3
    NCT00536341 SCRI Development Innovations, LLC|Celgene Corporation|Genentech, Inc. Chronic Lymphocytic Leukemia January 2008 Phase 1|Phase 2
    NCT01132989 Florida Academic Dermatology Centers|Celgene Corporation Cutaneous T Cell Lymphoma May 2010 Phase 2
    NCT02405364 University Hospital, Toulouse|Onyx Therapeutics, Inc.|Celgene Multiple Myeloma February 2014 Phase 2
    NCT01412307 Fondazione Giovanni Pascale Recurrent Adult Hodgkin Lymphoma July 2011 Phase 1|Phase 2
    NCT01545804 National Taiwan University Hospital Liver Cancer August 2011 Phase 2
    NCT02252172 Janssen Research & Development, LLC Multiple Myeloma February 16, 2015 Phase 3
    NCT00727415 Gruppo Italiano Malattie EMatologiche dell'Adulto Chronic Lymphocytic Leukemia February 2008 Phase 1|Phase 2
    NCT00833534 Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) Leukemia|Lymphoma February 2009 Phase 2
    NCT02697344 Mayo Clinic|National Cancer Institute (NCI) Recurrent Plasma Cell Myeloma April 14, 2017 Phase 1|Phase 2
    NCT02619682 Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) Plasma Cell Myeloma|Transplant-Related Carcinoma December 30, 2015 Phase 2
    NCT02705638 Mayo Clinic|Celgene Corporation Immunoglobulin G Subclass 4 Related Disease|IgG4-related Disease|Autoimmune Pancreatitis|IgG4-related Sclerosing Cholangitis|Retroperitoneal Fibrosis April 2016 Phase 1
    NCT00679367 Boston Medical Center Multiple Myeloma May 2008 Phase 2
    NCT01891643 Bristol-Myers Squibb|Abbott Newly Diagnosed, Previously Untreated Multiple Myeloma September 30, 2013 Phase 3
    NCT00445692 Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma|Refractory Plasma Cell Myeloma January 10, 2007 Phase 2
    NCT01351896 National Cancer Institute (NCI) Chronic Lymphocytic Leukemia|Stage 0 Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage I Small Lymphocytic Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Small Lymphocytic Lymphoma September 2011 Phase 2
    NCT00322985 AHS Cancer Control Alberta|Celgene Corporation|Alberta Cancer Foundation T-cell Lymphoma June 2006 Phase 2
    NCT02253316 Washington University School of Medicine|Millennium Pharmaceuticals, Inc. Multiple Myeloma January 20, 2015 Phase 2
    NCT02992522 Beth Christian|Celgene|Genentech, Inc.|Ohio State University Comprehensive Cancer Center B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3a Follicular Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Transformed Recurrent Non-Hodgkin Lymphoma February 21, 2017 Phase 1
    NCT00607581 IRCCS Policlinico S. Matteo|Celgene Corporation Amyloidosis February 2008 Phase 2
    NCT01016600 Washington University School of Medicine|Celgene Corporation Leukemia, Myeloid, Acute April 2010 Phase 1|Phase 2
    NCT02897830 University Hospital, Toulouse|Takeda|Celgene Multiple Myeloma September 2016 Phase 2
    NCT01049945 Mayo Clinic Refractory Multiple Myeloma February 2010 Phase 1|Phase 2
    NCT02389543 Karyopharm Therapeutics Inc Multiple Myeloma July 2015 Phase 1|Phase 2
    NCT00067743 Celgene Corporation|Celgene Complex Regional Pain Syndrome (RSD) August 2003 Phase 2
    NCT01183663 M.D. Anderson Cancer Center|Celgene Advanced Cancers August 2010 Phase 1
    NCT01650701 The Lymphoma Academic Research Organisation|Celgene Corporation Follicular Lymphoma February 2012 Phase 3
    NCT00482911 National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) Intraocular Melanoma|Malignant Conjunctival Neoplasm April 2007 Phase 2
    NCT02389517 University of Chicago|National Cancer Institute (NCI)|Multiple Myeloma Research Foundation Plasma Cell Myeloma|Residual Disease March 2015 Phase 2
    NCT01954784 Case Comprehensive Cancer Center|National Cancer Institute (NCI) Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma October 7, 2013 Phase 1
    NCT00628238 Chronic Lymphocytic Leukemia Research Consortium|Celgene Corporation Chronic Lymphocytic Leukemia|CLL|Untreated|Front-line|First-Line|Initial Therapy February 2008 Phase 2
    NCT03031483 International Extranodal Lymphoma Study Group (IELSG) Mucosa Associated Lymphoid Tissue (MALT) Lymphoma April 3, 2017 Phase 2
    NCT02441686 Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc.|Celgene Multiple Myeloma December 2015 Phase 2
    NCT01850524 Millennium Pharmaceuticals, Inc.|Takeda Multiple Myeloma May 17, 2013 Phase 3
    NCT01123356 Medical University of South Carolina|GlaxoSmithKline|Celgene Corporation Chronic Lymphocytic Leukemia May 2010 Phase 2
    NCT00540644 Attaya Suvannasankha|Celgene|Indiana University Multiple Myeloma October 2007 Phase 2
    NCT01349569 Sidney Kimmel Comprehensive Cancer Center|Celgene Corporation Multiple Myeloma January 2012 Phase 2
    NCT02340936 Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Celgene Corporation|Dynamic Science S.L.|Thermo Fisher Scientific Diffuse Large B-cell Lymphoma January 2011 Phase 1|Phase 2
    NCT00480363 PETHEMA Foundation|Celgene Corporation Multiple Myeloma May 2007 Phase 3
    NCT00915408 King's College Hospital NHS Trust Multiple Myeloma September 2006 Phase 1|Phase 2
    NCT02802943 University Hospital Tuebingen|Robert Bosch Gesellschaft für Medizinische Forschung mbH|Klinikum Stuttgart Leukemia, Chronic Lymphatic October 2016 Phase 2
    NCT02309515 Mayo Clinic|National Cancer Institute (NCI) Monoclonal B-Cell Lymphocytosis|Stage 0 Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage I Small Lymphocytic Lymphoma June 2015 Phase 2
    NCT01393756 The Lymphoma Academic Research Organisation|Centre Henri Becquerel Follicular Lymphoma December 2010 Phase 2
    NCT01383928 Millennium Pharmaceuticals, Inc.|Takeda Multiple Myeloma October 31, 2011 Phase 1|Phase 2
    NCT01169337 National Cancer Institute (NCI) Light Chain Deposition Disease|Smoldering Plasma Cell Myeloma October 5, 2010 Phase 3
    NCT01649791 Roswell Park Cancer Institute|National Cancer Institute (NCI)|Celgene Corporation B-cell Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Stage 0 Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia January 2010
    NCT00939510 Robert Dreicer MD|National Cancer Institute (NCI)|Case Comprehensive Cancer Center Prostate Cancer July 2005 Phase 1|Phase 2
    NCT00987493 Swiss Group for Clinical Cancer Research Lymphoma September 2009 Phase 1|Phase 2
    NCT02633137 Memorial Sloan Kettering Cancer Center|Celgene Corporation Mantle Cell Lymphoma|Untreated December 14, 2015 Phase 2
    NCT02341014 Memorial Sloan Kettering Cancer Center|University of Nebraska T-cell Lymphomas|Relapsed or Refractory January 2015 Phase 1|Phase 2
    NCT02281279 Mayo Clinic|National Cancer Institute (NCI) B-cell Adult Acute Lymphoblastic Leukemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|R October 2016 Phase 1|Phase 2
    NCT02213913 University of Chicago|National Cancer Institute (NCI) Adult Grade III Lymphomatoid Granulomatosis|B-cell Chronic Lymphocytic Leukemia|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Conti July 2014 Phase 1|Phase 2
    NCT02986451 Sun Yat-sen University|China Food and Drug Administration Relapse/Refractory Multiple Myeloma December 2016 Phase 2
    NCT01681537 Massachusetts General Hospital Acute Myelogenous Leukemia September 2012 Phase 1
    NCT01045928 Case Comprehensive Cancer Center Adult Non-Hodgkin Lymphoma|Adult Grade III Lymphomatoid Granulomatosis|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous January 2010 Phase 1
    NCT01881789 Amgen Multiple Myeloma August 2013 Phase 1|Phase 2
    NCT03173092 Millennium Pharmaceuticals, Inc.|Takeda Multiple Myeloma August 31, 2017 Phase 4
    NCT01053806 Tel-Aviv Sourasky Medical Center Myelodysplastic Syndrome August 2011 Phase 2
    NCT02128061 The Lymphoma Academic Research Organisation Diffuse Large B Cell Lymphoma August 2014 Phase 3
    NCT01005979 Emory University|Celgene Corporation Leukemia, Lymphocytic, Chronic, B-Cell|Chronic Lymphocytic Leukemia|Lymphoma, Small Lymphocytic July 2010 Phase 1
    NCT02076009 Janssen Research & Development, LLC Multiple Myeloma May 23, 2014 Phase 3
    NCT01197560 Celgene Diffuse Large B-cell Lymphoma September 1, 2010 Phase 2|Phase 3
    NCT00419250 Celgene Corporation Chronic Lymphocytic Leukemia|Leukemia, B-Cell, Chronic December 2006 Phase 1
    NCT00238238 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Lymphoma March 2006 Phase 2
    NCT01206205 University Hospital, Toulouse|Celgene Corporation|Janssen-Cilag Ltd. Multiple Myeloma August 2009 Phase 2
    NCT00772915 Mayo Clinic|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm December 2008 Phase 2
    NCT01749969 Sanofi Plasma Cell Myeloma February 6, 2013 Phase 1
    NCT01575860 Abramson Cancer Center of the University of Pennsylvania Lymphoma April 2012 Phase 1|Phase 2
    NCT01166035 Medical University Innsbruck|Celgene Corporation|Innsbruck - Tyrolean Working Group of Experimental Oncology (TEXO) Solid Tumors March 2010 Phase 1|Phase 2
    NCT03011814 City of Hope Medical Center|National Cancer Institute (NCI) Folliculotropic Mycosis Fungoides|Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified|Sezary Syndrome|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma February 14, 2017 Phase 1|Phase 2
    NCT01054144 H. Lee Moffitt Cancer Center and Research Institute|Celgene Multiple Myeloma January 2010 Phase 2
    NCT01711554 National Cancer Institute (NCI) Recurrent Neuroblastoma|Stage 4 Neuroblastoma February 4, 2013 Phase 1
    NCT02492750 Mayo Clinic|National Cancer Institute (NCI) Indolent Plasma Cell Myeloma|Plasma Cell Myeloma|Smoldering Plasma Cell Myeloma April 2016 Phase 1|Phase 2
    NCT01042704 Robert Redner, MD|Cephalon|University of Pittsburgh Myeloma February 2008 Phase 1
    NCT03118466 Massachusetts General Hospital|Celgene AML August 31, 2017 Phase 2
    NCT00942578 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Metastatic Prostate Cancer July 16, 2009 Phase 2
    NCT00602836 Mayo Clinic|National Cancer Institute (NCI) Leukemia|Lymphoma February 2008 Phase 2
    NCT01531998 M.D. Anderson Cancer Center|Janssen Services, LLC Myeloma May 2012 Phase 1|Phase 2
    NCT01194791 PETHEMA Foundation Primary Systemic Amyloidosis October 2010 Phase 2
    NCT01816971 University of Chicago|National Cancer Institute (NCI) Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma January 2013 Phase 2
    NCT01794039 Mayo Clinic|National Cancer Institute (NCI) Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma March 2014 Phase 2
    NCT02206503 Fondazione Neoplasie Sangue Onlus Multiple Myeloma March 2013 Phase 2
    NCT02880228 Mayo Clinic|National Cancer Institute (NCI) Plasma Cell Myeloma September 16, 2016 Phase 2
    NCT00644228 National Cancer Institute (NCI) DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma April 2008 Phase 3
    NCT01686386 Gruppo Italiano Studio Linfomi Multiple Myeloma February 2010 Phase 1|Phase 2
    NCT00792077 M.D. Anderson Cancer Center Leukemia|CLL November 2008
    NCT00477750 Mayo Clinic|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm June 2005 Phase 1|Phase 2
    NCT01217957 Millennium Pharmaceuticals, Inc.|Takeda Multiple Myeloma November 2010 Phase 1|Phase 2
    NCT00567229 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm November 2007 Phase 2
    NCT00642954 Merck Sharp & Dohme Corp. Relapsed or Refractory Multiple Myeloma February 2008 Phase 1
    NCT01199575 University of California, San Diego|Celgene Corporation Chronic Lymphocytic Leukemia|CLL August 2010 Phase 2
    NCT01125176 Weill Medical College of Cornell University|Celgene Chronic Lymphocytic Leukemia May 2012 Phase 2
    NCT01303965 Sherif S. Farag|Celgene Corporation|Indiana University Multiple Myeloma February 7, 2011 Phase 1|Phase 2
    NCT01496976 H. Lee Moffitt Cancer Center and Research Institute|Novartis|Celgene Corporation Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma January 20, 2012 Phase 2
    NCT02921893 Mayo Clinic|National Cancer Institute (NCI) Plasmacytoma|POEMS Syndrome October 2016 Phase 2
    NCT01685814 Wuerzburg University Hospital|ClinAssess GmbH|Celgene Corporation Previously Untreated Symptomatic Multiple Myeloma May 2012 Phase 3
    NCT01754870 University of Wisconsin, Madison|Celgene Corporation|Genentech, Inc. Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL) November 2013 Phase 2
    NCT01191060 University Hospital, Toulouse|Dana-Farber Cancer Institute|Celgene Corporation|Janssen-Cilag Ltd. Myeloma October 2010 Phase 3
    NCT01919086 Memorial Sloan Kettering Cancer Center|Millennium Pharmaceuticals, Inc.|Hartford Hospital Multiple Myeloma (MM) August 2013 Phase 2
    NCT02375555 Dana-Farber Cancer Institute|Bristol-Myers Squibb Multiple Myeloma May 2015 Phase 2
    NCT00860457 Georgetown University|Celgene Corporation Chronic Lymphocytic Leukemia February 2008 Phase 2
    NCT01093196 Fondazione Neoplasie Sangue Onlus Multiple Myeloma October 2009 Phase 3
    NCT01497496 H. Lee Moffitt Cancer Center and Research Institute|Novartis|Celgene Corporation Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma January 2012 Phase 2
    NCT01743859 University of Colorado, Denver|Celgene Acute Myeloid Leukemia December 6, 2012 Phase 2
    NCT02215980 Fondazione Neoplasie Sangue Onlus Multiple Myeloma July 2014 Phase 3
    NCT01732861 Celgene Leukemia Lymphocytic Chronic B-Cell December 28, 2012 Phase 1
    NCT01355705 Michaela Liedtke|Celgene Corporation|Stanford University Multiple Myeloma August 2011 Phase 1|Phase 2
    NCT02561273 University of Nebraska|National Cancer Institute (NCI) Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Hepatosplenic T-Cell Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Stage II Angioimmunoblastic T-cell Lymphoma|Stage II Enteropathy-Associated T-Cell Lymphoma|Stage III Angioimmunoblastic T-cell Lymphoma|Stage III Enteropathy-Associated T-Cell Lymphoma|Stage IV Angioimmunoblastic T-cell Lymphoma|Stage IV Enteropathy-Associated T-Cell Lymphoma October 2015 Phase 1|Phase 2
    NCT01564537 Millennium Pharmaceuticals, Inc.|Takeda Relapsed Multiple Myeloma|Refractory Multiple Myeloma August 1, 2012 Phase 3
    NCT02874742 Janssen Research & Development, LLC Multiple Myeloma August 29, 2016 Phase 2
    NCT03015922 University of Leeds|Myeloma UK|Oncolytics Biotech|Celgene Corporation Multiple Myeloma June 5, 2017 Phase 1
    NCT03212807 Singapore General Hospital|National Cancer Center Singapore, Singapore|National University Hospital, Singapore|Raffles Hospital, Singapore EBV Related Non-Hodgkin's Lymphoma|Primary CNS Lymphoma|Primary Testicular Lymphoma August 2017 Phase 2
    NCT00378105 Dana-Farber Cancer Institute|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Celgene Corporation|Millennium Pharmaceuticals, Inc. Multiple Myeloma September 2006 Phase 1|Phase 2
    NCT02159365 Bristol-Myers Squibb Multiple Myeloma March 2014 Phase 2
    NCT01501370 Tiziana Marangon|University of Turin, Italy Multiple Myeloma January 2012 Phase 2
    NCT00424229 Groupe Francophone des Myelodysplasies Myelodysplastic Syndromes October 2006 Phase 2
    NCT03015792 Mayo Clinic|National Cancer Institute (NCI) Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma March 10, 2017 Phase 1|Phase 2
    NCT01080391 Amgen Relapsed Multiple Myeloma July 2010 Phase 3
    NCT00378209 Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|Celgene Corporation|Millennium Pharmaceuticals, Inc. Multiple Myeloma August 2006 Phase 2
    NCT01208662 Paul G. Richardson, MD|Celgene Corporation|Millennium Pharmaceuticals, Inc.|Massachusetts General Hospital|Cape Cod Healthcare|Beth Israel Deaconess Medical Center|Emory University|University of Michigan|Fox Chase Cancer Center|Memorial Sloan Kettering Cancer Center|Fred Hutchinson Cancer Research Center|Barbara Ann Karmanos Cancer Institute|Duke University|University of California, San Francisco|University of Chicago|M.D. Anderson Cancer Center|UNC Lineberger Comprehensive Cancer Center|Roswell Park Cancer Institute|Stanford University|University of Mississippi Medical Center|Icahn School of Medicine at Mount Sinai|Wake Forest University Health Sciences|University of Arizona|OHSU Knight Cancer Institute|Eastern Maine Medical Center|University of California, San Diego|University of Alabama at Birmingham|University of Pittsburgh|Ochsner Health System|University of Texas Southwestern Medical Center|State University of New York - Downstate Medical Center|Newton-Wellesley Hospital|Baylor College of Medicine|City of Hope Medical Center|University of Florida|Northwell Health|H. Lee Moffitt Cancer Center and Research Institute|Vanderbilt University Medical Center|Ohio State University|Huntsman Cancer Institute|Columbia University|Dana-Farber Cancer Institute Multiple Myeloma September 2010 Phase 3
    NCT01965353 Dana-Farber Cancer Institute|Novartis Multiple Myeloma in Relapse October 2013 Phase 1
    NCT02077166 Pharmacyclics LLC.|Janssen Research & Development, LLC|Celgene Corporation Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma February 2014 Phase 1|Phase 2
    NCT00253344 Case Comprehensive Cancer Center|National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific June 2005 Phase 1
    NCT01217203 Innate Pharma Patients With Multiple Myeloma Experiencing a|First or Second Relapse September 2010 Phase 1
    NCT02765854 Emory University|Millennium Pharmaceuticals, Inc.|Multiple Myeloma Research Consortium Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma September 1, 2016 Phase 2
    NCT02886065 Massachusetts General Hospital|Celgene|OncoPep, Inc. Smoldering Multiple Myeloma November 2016 Phase 1
    NCT02579863 Merck Sharp & Dohme Corp. Multiple Myeloma October 19, 2015 Phase 3
    NCT01668719 Southwest Oncology Group|National Cancer Institute (NCI) DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma November 2012 Phase 1|Phase 2
    NCT00445484 Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm January 2007 Phase 2
    NCT01060384 University of Nebraska|Celgene Corporation|GlaxoSmithKline Non-Hodgkin's Lymphoma March 2010 Phase 1|Phase 2
    NCT02802163 H. Lee Moffitt Cancer Center and Research Institute|Novartis|Amgen Multiple Myeloma June 2017 Phase 1|Phase 2
    NCT02446236 Hackensack University Medical Center Mantle Cell Lymphoma May 2015 Phase 1
    NCT01208051 National Cancer Institute (NCI) Recurrent Thyroid Gland Carcinoma|Stage I Thyroid Gland Follicular Carcinoma|Stage I Thyroid Gland Papillary Carcinoma|Stage II Thyroid Gland Follicular Carcinoma|Stage II Thyroid Gland Papillary Carcinoma|Stage III Thyroid Gland Follicular Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage IV Thyroid Gland Follicular Carcinoma|Stage IV Thyroid Gland Papillary Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma|Stage IVA Thyroid Gland Papillary Carcinoma|Stage IVB Thyroid Gland Folli September 9, 2010 Phase 1|Phase 2
    NCT00807599 Memorial Sloan Kettering Cancer Center|Tufts Medical Center|Lahey Clinic Multiple Myeloma December 10, 2008 Phase 2
    NCT02203643 Silvio Aime|University of Turin, Italy MULTIPLE MYELOMA (MM) February 2015 Phase 2
    NCT02460276 Lund University Hospital|Celgene|Janssen, LP|Nordic Lymphoma Group Relapsed/Refractory Mantle Cell Lymphoma April 2015 Phase 2
    NCT00698776 Yale University|Kyowa Hakko Kirin Co., Ltd|Celgene Myeloma April 2009 Phase 1
    NCT03031730 National Cancer Institute (NCI) Hypercalcemia|Plasmacytoma|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma October 27, 2017 Phase 1
    NCT00478218 Mayo Clinic|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm July 2006 Phase 2
    NCT02903381 Dana-Farber Cancer Institute|Bristol-Myers Squibb|Multiple Myeloma Research Consortium Smoldering Multiple Myeloma October 2016 Phase 2
    NCT02353468 University of Colorado, Denver Refractory Plasma Cell Myeloma December 2009 Phase 2
    NCT01035463 University of Nebraska|National Cancer Institute (NCI) Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Imm November 2009 Phase 1|Phase 2
    NCT00864942 Georgetown University|Celgene Corporation|Cephalon Chronic Lymphocytic Leukemia|Non-Hodgkin's Lymphoma February 2009 Phase 1
    NCT03012880 Mayo Clinic|National Cancer Institute (NCI) Plasma Cell Myeloma April 12, 2017 Phase 2
    NCT02685826 Celgene Multiple Myeloma April 25, 2016 Phase 1
    NCT00538824 Weill Medical College of Cornell University|Celgene Multiple Myeloma December 2007 Phase 2
    NCT01629082 National Heart, Lung, and Blood Institute (NHLBI)|Celgene Corporation|National Institutes of Health Clinical Center (CC) Myeldysplastic Syndrome (MDS)|Chronic Myelomonocytic Leukemia|Bone Marrow Diseases|Neutropenia|Acute Myeloid Leukemia (AML) June 5, 2012 Phase 1
    NCT01742793 Yale University|Peter MacCallum Cancer Centre, Australia Hodgkin's Lymphoma|Mature T-cell Lymphoma|Multiple Myeloma October 2012 Phase 1|Phase 2
    NCT00902915 Austrian Forum Against Cancer Multiple Myeloma Light Chain Induced Renal Insufficiency May 2009 Phase 2
    NCT02335983 Amgen Multiple Myeloma April 2015 Phase 1
    NCT00551928 Fondazione Neoplasie Sangue Onlus Multiple Myeloma|Newly Diagnosed Patients June 2007 Phase 3
    NCT02631577 Hoffmann-La Roche Lymphoma, Follicular December 31, 2015 Phase 1
    NCT01865110 The Lymphoma Academic Research Organisation Mantle Cell Lymphoma November 2013 Phase 3
    NCT00415116 The Cleveland Clinic|National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific August 2004 Phase 1
    NCT00415064 AEterna Zentaris Multiple Myeloma December 2006 Phase 1
    NCT01522976 National Cancer Institute (NCI) Chronic Myelomonocytic Leukemia|Chronic Myelomonocytic Leukemia-1|Chronic Myelomonocytic Leukemia-2|Myelodysplastic Syndrome With Excess Blasts|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Previously Treated Myelodysplastic Syndrome March 1, 2012 Phase 2
    NCT00096525 Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Kidney Cancer July 2004 Phase 2
    NCT00522392 National Cancer Institute (NCI) Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma September 2007 Phase 3
    NCT01731886 Columbia University Multiple Myeloma September 2012 Phase 4
    NCT03050450 Johns Hopkins All Children's Hospital Central Nervous System Tumors August 10, 2016 Phase 1
    NCT01307592 Auxilio Mutuo Cancer Center|National Cancer Institute (NCI) Lymphoma February 2011 Phase 2
    NCT01518465 University of Southern California|National Cancer Institute (NCI)|Celgene Corporation Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma January 9, 2012 Phase 2
    NCT00843310 New York University School of Medicine|Celgene Multiple Myeloma November 2008 Phase 2
    NCT00974233 University of Wisconsin, Madison|Celgene Corporation Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma October 2009 Phase 2
    NCT00687674 Mayo Clinic|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm August 2008 Phase 1|Phase 2
    NCT01554852 University of Leeds|Celgene|Merck Sharp & Dohme Corp.|Amgen Multiple Myeloma May 2010 Phase 3
    NCT00482261 Peter MacCallum Cancer Centre, Australia|Celgene Corporation Multiple Myeloma June 2007 Phase 2
    NCT02495922 University of Heidelberg Medical Center Multiple Myeloma June 2015 Phase 3
    NCT00555100 Celgene Corporation Multiple Myeloma July 2007 Phase 1
    NCT00621400 Nantes University Hospital Amyloidosis January 2008 Phase 1|Phase 2
    NCT01562405 Massachusetts General Hospital|Multiple Myeloma Research Consortium Multiple Myeloma May 2012 Phase 1
    NCT01239797 Bristol-Myers Squibb|AbbVie Lymphoma|Multiple Myeloma March 28, 2011 Phase 3
    NCT01615029 Janssen Research & Development, LLC Multiple Myeloma January 2012 Phase 2
    NCT00724568 University of Michigan Cancer Center Multiple Myeloma May 2008 Phase 1|Phase 2
    NCT01126450 Case Comprehensive Cancer Center Colon Cancer|Rectal Cancer October 2009 Phase 1
    NCT00564889 Mayo Clinic|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm December 2007 Phase 2
    NCT00899431 M.D. Anderson Cancer Center|Celgene Corporation Chronic Lymphocytic Leukemia May 2009 Phase 2
    NCT02628405 Academic and Community Cancer Research United|National Cancer Institute (NCI) CD20 Positive|Diffuse Large B-Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Transformed Recurrent Non-Hodgkin Lymphoma May 2016 Phase 1|Phase 2
    NCT00907452 Intergroupe Francophone du Myelome Myeloma April 2009
    NCT00560391 Bristol-Myers Squibb Multiple Myeloma May 2008 Phase 1
    NCT01782963 Massachusetts General Hospital Multiple Myeloma March 2013 Phase 2
    NCT01352962 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer April 5, 2011 Phase 1
    NCT00151203 Weill Medical College of Cornell University|Celgene Corporation Multiple Myeloma December 2004 Phase 2
    NCT00884546 Bristol-Myers Squibb|Exelixis Advanced Cancer, Various, NOS July 2009 Phase 1
    NCT00784927 Mayo Clinic|National Cancer Institute (NCI) Lymphoma November 2008 Phase 2
    NCT01091831 Fondazione Neoplasie Sangue Onlus Multiple Myeloma July 2009 Phase 3
    NCT00602641 National Cancer Institute (NCI) Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma February 2008 Phase 3
    NCT00098475 National Cancer Institute (NCI) DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma October 26, 2004 Phase 3
    NCT01559935 Weill Medical College of Cornell University|Onyx Therapeutics, Inc. Multiple Myeloma March 2012 Phase 2
    NCT02928419 Associazione Qol-one Myelodysplastic Syndromes May 2015 Phase 2
    NCT02843074 SCRI Development Innovations, LLC|Bristol-Myers Squibb Multiple Myeloma September 21, 2016 Phase 2
    NCT02279394 Dana-Farber Cancer Institute|Bristol-Myers Squibb|Celgene Smoldering Myeloma|Smoldering Multiple Myeloma December 2014 Phase 2
    NCT00525447 Seattle Genetics, Inc.|Genentech, Inc. Multiple Myeloma August 2007 Phase 1
    NCT01863550 ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma November 2013 Phase 3
    NCT02142049 Pharmacyclics LLC.|Celgene Corporation Diffuse Large B Cell Lymphoma Relapsed|Diffuse Large B Cell Lymphoma Refractory May 2014 Phase 1|Phase 2
    NCT01415752 Eastern Cooperative Oncology Group|National Cancer Institute (NCI) Lymphoma|Neurotoxicity|Therapy-related Toxicity May 2012 Phase 2
    NCT01335399 Bristol-Myers Squibb|AbbVie Multiple Myeloma May 18, 2011 Phase 3
    NCT01856192 National Cancer Institute (NCI) CD20 Positive|Stage II Diffuse Large B-Cell Lymphoma|Stage III Diffuse Large B-Cell Lymphoma|Stage IV Diffuse Large B-Cell Lymphoma August 27, 2013 Phase 2
    NCT00617591 H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation|Ortho Biotech Clinical Affairs, L.L.C. Multiple Myeloma January 2008 Phase 2
    NCT01359657 Bristol-Myers Squibb Multiple Myeloma September 2011 Phase 1
    NCT00114101 National Cancer Institute (NCI) DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma|Refractory Plasma Cell Myeloma|Smoldering Plasma Cell Myeloma December 15, 2004 Phase 3
    NCT02573896 New Approaches to Neuroblastoma Therapy Consortium|M.D. Anderson Cancer Center|United Therapeutics Neuroblastoma June 2017 Phase 1
    NCT01121757 Duke University|Celgene Follicular Lymphoma|Marginal Zone Lymphoma April 2010 Phase 2
    NCT02600897 Hoffmann-La Roche Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma March 23, 2016 Phase 1|Phase 2
    NCT01208766 Stichting Hemato-Oncologie voor Volwassenen Nederland|European Myeloma Network|GIMEMA (Italian Group for Adult Hematologic Diseases)|DSMM (Deutsche Studiengruppe Multiples Myelom)|NMSG (Nordic Myeloma Study Group)|Central European Myeloma Study Group Multiple Myeloma January 2011 Phase 3
    NCT01075321 Mayo Clinic Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Grade 1 Fo January 2011 Phase 1|Phase 2
    NCT02916771 Dana-Farber Cancer Institute|Celgene|Takeda Smoldering Multiple Myeloma October 2016 Phase 2
    NCT02285062 Celgene Lymphoma, Large B-Cell, Diffuse January 21, 2015 Phase 3
    NCT02937571 Memorial Sloan Kettering Cancer Center|Onyx/Amgen|Celgene Multiple Myeloma October 2016 Phase 1|Phase 2
    NCT00036894 National Cancer Institute (NCI) Brain and Central Nervous System Tumors March 2002 Phase 1
    NCT01155583 Case Comprehensive Cancer Center|National Cancer Institute (NCI) Refractory Multiple Myeloma June 2010 Phase 1|Phase 2
    NCT00031941 National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific April 2002 Phase 1
    NCT02983097 Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH|Celgene|Amgen Diffuse Large B-cell Lymphoma (DLBCL)|Follicular Lymphoma Grade III (FL III°)|Mantle Cell Lymphoma (MCL), Blastoid Variant|Burkitt Lymphoma (BL)|Aggressive Marginal Zone Lymphoma (MZL) November 2010 Phase 1|Phase 2
    NCT02280525 M.D. Anderson Cancer Center|The Leukemia and Lymphoma Society|Celgene Corporation Leukemia March 2015 Phase 1
    NCT00064038 Southwest Oncology Group|National Cancer Institute (NCI) Multiple Myeloma|Plasma Cell Neoplasm November 2004 Phase 3
    NCT02969837 University of Chicago|Bristol-Myers Squibb|Amgen Multiple Myeloma September 2017 Phase 2
    NCT01916252 PETHEMA Foundation|Janssen, LP|Celgene|Pierre Fabre Medicament Multiple Myeloma September 2013 Phase 3
    NCT01216683 Eastern Cooperative Oncology Group|National Cancer Institute (NCI) Lymphoma December 2010 Phase 2
    NCT02406144 PETHEMA Foundation|Celgene|Millennium Pharmaceuticals, Inc. Multiple Myeloma November 2014 Phase 3
    NCT00908232 Janssen-Cilag International NV Multiple Myeloma May 2008 Phase 2
    NCT00538733 Weill Medical College of Cornell University|Celgene Multiple Myeloma October 2007 Phase 2
    NCT00305812 NCIC Clinical Trials Group|Canadian Cancer Trials Group Multiple Myeloma and Plasma Cell Neoplasm December 2005 Phase 2
    NCT02954406 Millennium Pharmaceuticals, Inc.|Takeda Lymphoma, Non-Hodgkin April 10, 2017 Phase 1
    NCT01617213 University of Virginia Multiple Myeloma April 2012 Phase 2
    NCT03003520 Celgene Lymphoma, Large B-Cell, Diffuse February 28, 2017 Phase 2
    NCT01484626 Loyola University Multiple Myeloma May 2011 Phase 1|Phase 2
    NCT00074282 Eastern Cooperative Oncology Group|National Cancer Institute (NCI) Leukemia December 2004 Phase 2
    NCT00460031 Case Comprehensive Cancer Center|National Cancer Institute (NCI) Prostate Cancer September 1, 2006 Phase 2
    NCT02728102 National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program Multiple Myeloma July 2016 Phase 2
    NCT01010243 University of Regensburg|ClinAssess GmbH Multiple Myeloma October 2009 Phase 1|Phase 2
    NCT02516696 Weill Medical College of Cornell University|Celgene Corporation Multiple Myeloma February 2016 Phase 3
    NCT01301820 French Innovative Leukemia Organisation|Celgene Corporation Acute Myeloid Leukemia January 2011 Phase 2
    NCT00779922 Poitiers University Hospital Multiple Myeloma|Impaired Renal Function November 2008 Phase 2
    NCT01647165 National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc.|National Institutes of Health Clinical Center (CC) Multiple Myeloma July 11, 2012 Phase 2
    NCT00405756 Celgene Corporation Newly Diagnosed Multiple Myeloma January 2007 Phase 3
    NCT02219178 Cancer Trials Ireland Multiple Myeloma November 2014 Phase 2
    NCT01393964 Bristol-Myers Squibb|AbbVie Multiple Myeloma January 2012 Phase 1
    NCT03104842 University Hospital Tuebingen Multiple Myeloma July 2017 Phase 2
    NCT02544308 University College, London|Cancer Research UK|Celgene Plasmacytoma March 10, 2017 Phase 3
    NCT02426723 JW Pharmaceutical Multiple Myeloma October 2015 Phase 1
    NCT02525250 Institut Paoli-Calmettes Acute Myeloid Leukemia or Myelodysplasic Syndrome December 2012
    NCT01056679 University of Cologne Hodgkin Lymphoma April 2010 Phase 1
    NCT00112827 City of Hope Medical Center Refractory Multiple Myeloma|Smoldering Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma November 2004 Phase 1|Phase 2
    NCT02516423 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc.|Biologics, Inc. Solitary Osseous Plasmacytoma December 2015 Phase 3
    NCT00670358 Mayo Clinic|National Cancer Institute (NCI) Lymphoma August 2008 Phase 1|Phase 2
    NCT02911142 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Primary Effusion Lymphoma|B-Cell Lymphoma September 15, 2016 Phase 1|Phase 2
    NCT00602459 National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|NCIC Clinical Trials Group|Southwest Oncology Group Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia January 2008 Phase 2
    NCT03223610 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Lymphoma|Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma|Burkitt Lymphoma July 28, 2017 Phase 1
    NCT02575144 PETHEMA Foundation|Cabyc, S.L. Multiple Myeloma September 2015 Phase 3
    NCT00742560 AbbVie (prior sponsor, Abbott)|Bristol-Myers Squibb|AbbVie Hematologic Cancer August 2008 Phase 2
    NCT02368301 Bristol-Myers Squibb Multiple Myeloma
    NCT02415413 PETHEMA Foundation|Celgene Corporation|Amgen Smoldering Multiple Myeloma May 2015 Phase 2
    NCT02513186 Sanofi Plasma Cell Myeloma September 30, 2015 Phase 1
    NCT02481934 Joaquín Martínez López, MD, PhD|Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Hospital Universitario 12 de Octubre Multiple Myeloma March 2013 Phase 1
    NCT01460420 European Myeloma Network Hematologic Malignancies|Multiple Myeloma November 2011 Phase 1|Phase 2
    NCT01245673 University of Pennsylvania Myeloma April 2011 Phase 2
    NCT01242930 Geron Corporation Multiple Myeloma November 2010 Phase 2
    NCT01481194 Vejle Hospital|The University of Hong Kong Multiple Myeloma November 2011 Phase 2
    NCT00507442 Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Multiple Myeloma August 2007 Phase 1|Phase 2
    NCT02856438 Bristol-Myers Squibb|AbbVie Multiple Myeloma
    NCT03000634 University of Arkansas Multiple Myeloma May 2017 Phase 2
    NCT02530515 M.D. Anderson Cancer Center Leukemia|Chronic Lymphocytic Leukemia December 18, 2015 Phase 2
    NCT02891811 Arbeitsgemeinschaft medikamentoese Tumortherapie|Amgen Multiple Myeloma March 10, 2017 Phase 2
    NCT01055301 Southwest Oncology Group|National Cancer Institute (NCI) Multiple Myeloma|Plasma Cell Myeloma July 2011 Phase 2
    NCT01953692 Merck Sharp & Dohme Corp. Myelodysplastic Syndrome|Multiple Myeloma|Hodgkin Lymphoma|Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Primary Mediastinal B-Cell Lymphoma November 22, 2013 Phase 1
    NCT03168100 University of Arkansas Multiple Myeloma July 2017 Phase 2
    NCT02060656 Royal Marsden NHS Foundation Trust|Celgene Corporation Diffuse Large B-Cell Lymphoma September 2013 Phase 2
    NCT02343042 Karyopharm Therapeutics Inc Multiple Myeloma October 2015 Phase 1|Phase 2
    NCT01729091 M.D. Anderson Cancer Center|Celgene Myeloma June 2013 Phase 1|Phase 2
    NCT02036502 Merck Sharp & Dohme Corp. Multiple Myeloma February 14, 2014 Phase 1
    NCT01421186 MorphoSys AG Multiple Myeloma July 2011 Phase 1|Phase 2
    NCT01706666 Mayo Clinic Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma December 2012 Phase 2
    NCT01342692 Assistance Publique - Hôpitaux de Paris MDS June 2011 Phase 2
    NCT02733042 Celgene Corporation Lymphoma|Leukemia, Lymphocytic, Chronic, B-Cell May 2016 Phase 1|Phase 2
    NCT01827137 Memorial Sloan Kettering Cancer Center|IND transferred to Sellas Multiple Myeloma April 2013
    NCT03188172 University of Leeds|Myeloma UK|Celgene|Janssen, LP Multiple Myeloma July 1, 2017 Phase 2
    NCT02431208 Hoffmann-La Roche Multiple Myeloma July 22, 2015 Phase 1
    NCT01215344 Vanderbilt-Ingram Cancer Center Multiple Myeloma November 2010 Phase 2
    NCT00495872 M.D. Anderson Cancer Center Solid Tumors June 2007 Phase 1
    NCT02419118 Vejle Hospital Multiple Myeloma January 2015 Phase 2|Phase 3
    NCT02206425 Oncotherapeutics|Millennium: The Takeda Oncology Company Multiple Myeloma September 2014 Phase 1|Phase 2
    NCT02666209 Dana-Farber Cancer Institute|Bristol-Myers Squibb Multiple Myeloma in Relapse|Multiple Myeloma
    NCT02331368 University of Michigan Cancer Center|Medical College of Wisconsin Multiple Myeloma June 2015 Phase 2
    NCT03019640 M.D. Anderson Cancer Center B-Cell Non-Hodgkin Lymphoma September 2017 Phase 2
    NCT01619761 M.D. Anderson Cancer Center|Celgene|American Cancer Society, Inc.|CLL Global Research Foundation Leukemia|Chronic Lymphocytic Leukemia May 3, 2013 Phase 1
    NCT01088048 Gilead Sciences Indolent Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma April 2010 Phase 1
    NCT02719613 Bristol-Myers Squibb|AbbVie Multiple Myeloma July 11, 2016 Phase 2
    NCT01537861 Washington University School of Medicine Multiple Myeloma June 2012 Early Phase 1
    NCT03004287 University of Arkansas|Janssen, LP Multiple Myeloma July 1, 2017 Phase 2
    NCT02721043 Nina Bhardwaj|Icahn School of Medicine at Mount Sinai Solid Tumors April 2016 Phase 1
    NCT03100877 City of Hope Medical Center|National Cancer Institute (NCI) Plasma Cell Leukemia in Remission|Plasma Cell Myeloma May 24, 2017 Phase 1|Phase 2
    NCT01659658 Millennium Pharmaceuticals, Inc.|Takeda Relapsed or Refractory Systemic Light Chain Amyloidosis December 26, 2012 Phase 3
    NCT01998971 Janssen Research & Development, LLC Multiple Myeloma February 18, 2014 Phase 1
    NCT02265510 Incyte Corporation Advanced Cancer August 2014 Phase 1|Phase 2
    View MoreCollapse
    References
    Preparing Stock Solutions
    Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
    1 mM 3.8571 mL 19.2857 mL 38.5713 mL
    5 mM 0.7714 mL 3.8571 mL 7.7143 mL
    10 mM 0.3857 mL 1.9286 mL 3.8571 mL
    Cell Assay
    [3]

    Lenalidomide is solubilized in DMSO and stored, and then diluted with appropriate media (DMSO 0.1%) before use[1].

    Cell lines NCI-H929 and U266, and DF15 cells are grown in RPMI-I640 medium containing 10% (V/V) heat-inactivated fetal bovine serum supplemented with 2 mM glutamine. To produce Lenalidomide resistant cell lines, NCI-H929 cells are treated continuously (fresh Lenalidomide is added every 3-4 days) with control (final 0.1% DMSO) or low-dose Lenalidomide (1 μM) for 2 months until the proliferation of cells is no longer inhibited by Lenalidomide (1 μM), as determined by cell viability (Vi-cell XR cell viability analyzer), cell proliferation by flow cytometry and cell cycle analysis (propidium iodide staining). After acquisition of resistance to 1 μM, the resistant H929 cell lines are treated with Lenalidomide (10 μM) for a further 4 months. After this period of time, the cell cultures achieved fully establish resistance up to high-dose Lenalidomide (30 μM). Prior to the experiments described here, H929 Lenalidomide-resistant cells are taken out of culture with compounds for 5-7 days before use[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [4]

    Lenalidomide is prepared in sterile PBS containing 1% hydrochloric acid (HCl) (Mice)[4].

    Mice[4]
    Imprinting control region (ICR) mice 8-10 weeks of age are used. Lenalidomide is incompletely soluble at 3.5 mg/mL and above in PBS containing 1% HCl, as visible particulates remained after thorough mixing. Therefore 3 mg/mL is selected as the maximum dosing solution concentration (with no visible particulates). Single, individual mice are initially dosed with 3, 10, or 15 mg/kg IV; 4.5, 15, or 22.5 mg/kg IP; and 9, 30, or 45 mg/kg PO. Additional mice (n=4) are then evaluated at the maximum dose achievable by volume and solubility of Lenalidomide in the dosing solution. All mice are monitored closely for 1 h and re-evaluated for toxicities 3, 6, and 24 h postdose. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    259.26

    Formula

    C₁₃H₁₃N₃O₃

    CAS No.

    191732-72-6

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: ≥ 35 mg/mL

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Purity: 99.98%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Lenalidomide
    Cat. No.:
    HY-A0003
    Quantity: